Aktuellt
SENASTE
Redeye is encouraged by Egetis Therapeutic’s announcement earlier today, stating that the FDA has granted Orphan Drug Designation (ODD) to Emcitate for treatment of Resistance to Thyroid Hormone type beta (RTH-β).
LÄS MER
